title: [Radiotherapy and intra-arterial chemotherapy of locally advanced hepatocellular carcinoma. Analysis of prognostic factors].
abstract: Prognostic factors in the treatment of local advanced hepatocellular carcinoma with radiotherapy, transcatheter arterial embolization and arterial infusion.
  
  
  OBJECTIVE
  The treatment effects of radiotherapy and combination modality therapy for the local advanced hepatocellular carcinoma (HCC) were retrospectively reviewed.
  
  
  METHODS
  Three hundred and fifty-six patients of HCC (187 recurrent cases after surgical resection) were treated by 1) radiotherapy only; 2) Bi-therapeutic method: hepatic artery ligation (HAL) and/or hepatic artery embolization (HAE) plus radiotherapy; and 3) tri-therapeutic method (bi-therapeutic method plus hepatic artery infusion) from 1975 to 1996. Kaplan-Meier method has been used to evaluate the survival rates.
  
  
  RESULTS
  There were no significant differences among these three treatment groups in the symptom relief rate, but the mean relief time period was much shorter in radiotherapy alone group (2.5 vs 44 months, P < 0.05). A lower tumor response rate was found in the radiotherapy alone group (P < 0.05), although that was similar for both primary or recurrent tumors (P > 0.05). There were evident differences in five-year survivals among these three treatment groups: 0% for radiotherapy alone, 22.8% for bi-therapeutic method and 38.8% for tri-therapeutic method (P < 0.01). The prognosis was influenced by Okuda classification.
  
  
  CONCLUSIONS
  Non-resectable local advanced HCC can be treated by the combination modality therapy, including radiotherapy, with a quite high cure rate. Radiotherapy alone can relief the symptoms.
authors.affiliation: Service d'oncologie, Hôpital Changhai, Shanghai, Chine.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Jin
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents